¼¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°Á "ºÎÀÎÁ¾¾çÇÐ" : 2019-12-15±³À°ÀÏÀÚ : 2019-12-15
±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç
±³À°ÁÖÁ¦ :
¼¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°Á "ºÎÀÎÁ¾¾çÇÐ"ÁÖÃÖ±â°ü : ¼¿ï´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : »êºÎÀΰú
´ã´çÀÚ : ÀÓÇö¿µ
¿¬¶ôó : 02-2072-2388
À̸ÞÀÏ :
hyrimobgy@nate.com ±³À°Á¾·ù : »êºÎÀΰúÀÇ»çÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 160¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:00~13:20 Endometrial cancer Á¤ÇöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:20~13:40 Ovarian cancer À̸¶¸®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:40~14:00 Risk reducing strategies ¼µ¿ÈÆ(¼¿ïÀÇ´ë)
Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:00~14:15 Discussion ()
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:15~14:35 Minimally invasive surgery after LACC trial ³ëÀçÈ«(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:35~14:55 Hyperthermic intraperitoneal chemotherapy ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:55~15:15 Role of lymphadenectomy in gynecologic cancers ±èÅÂÈÆ(¼¿ïÀÇ´ë)
Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:15~15:30 Discussion ()
ÈÞ½Ä 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:30~15:50 Coffee Break ()
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:50~16:10 Bevacizumab ¹èÀ縸(ÇѾçÀÇ´ë)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:10~16:30 PARP inhibitors ÀÌäÇü(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:30~16:50 Immune checkpoint inhibitors ±èÈñ½Â(¼¿ïÀÇ´ë)
Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:50~17:00 Discussion ()
±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 17:00~17:40 ¹«¾ùÀÌ ÃÖ¼±Àϱî? »êºÎÀΰú ÀÇ»ç·Î »ì¾Æ°¡±â ¼ÛÇöÁø(ºÎõ¼¿ï¿©¼ºº´¿ø)
±³À°½Ã°£ 12-15 17:40~17:50 ¸ÎÀ½¸» ()